Autophagy activated by the c-Jun N-terminal kinase-mediated pathway protects human prostate cancer PC3 cells from celecoxib-induced apoptosis

XIN ZHU¹, MI ZHOU², GUANYU LIU¹,³, XIAOLONG HUANG¹,³, WEIYANG HE¹, XIN GOU¹ and TAO JIANG²

Departments of ¹Urology, ²Respiratory Medicine and ³Molecular Oncology and Epigenetics, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, P.R. China

Received January 1, 2016; Accepted February 3, 2017

DOI: 10.3892/etm.2017.4287

Abstract. The aim of the present study was to investigate the role of autophagy in celecoxib-induced apoptosis in human hormone-insensitive prostate cancer cell line PC3 cells and to explore the underlying molecular mechanism leading to autophagic activation. A cell viability assay was applied to investigate the effect of various concentrations of celecoxib (0, 40, 60, 80, 100 and 120 µmol/l) on PC3 cells for 24 and 48 h, respectively. The 50% inhibitory concentration of celecoxib for 24 h was chosen for subsequent experiments. Annexin V-fluorescein isothiocyanate/propidium iodide double staining flow cytometry, as well as caspase 3 and poly (ADP-ribose) polymerase proteins detected by western blotting, were applied to analyze cellular apoptosis induced by celecoxib. Ultrastructural cellular changes observed by transmission electron microscopy and the level of LC-3 II and P62 detected by western blotting were used to determine the activation of autophagy. It was demonstrated that celecoxib induced apoptosis and activated autophagy in PC3 cells in a dose- and time-dependent manner. Furthermore, flow cytometry and western blotting were applied to elucidate whether the role of autophagy in celecoxib-induced apoptosis is protective or destructive. Blockade of autophagy markedly increased apoptosis, suggesting that celecoxib-activated autophagy was cytoprotective. Additionally, c-jun-N-terminal kinase (JNK) was demonstrated to have a role in autophagic activation, and suppression of JNK was able to reduce autophagy and increase apoptosis. In conclusion, the results of the present study indicate that celecoxib induces apoptosis in PC3 cells; however, celecoxib also activates JNK-mediated autophagy, which exerts cytoprotective effects in prostate cancer PC3 cells. Blockade of autophagy via the JNK-mediated pathway may provide a promising strategy for prostate cancer therapy.

Introduction

Prostate cancer is the second most common cancer and the sixth leading cause of cancer mortality worldwide (1). According to estimates of the American Cancer Society, the expected number of new cases of prostate cancer is 220,800, which accounted for ~25% of new cancer diagnoses in 2015. However, the expected number of prostate cancer deaths in 2015 was ~27,540, which was slightly less compared with the expected mortality rate of 29,480 in 2014 (2). Although patients with hormone-sensitive localized prostate cancer may experience successful outcomes with the application of surgery, radiotherapy or hormonal therapy, the disease inevitably progresses into castration-resistant and metastatic prostate cancer, negatively affecting quality of life and markedly reducing the survival rate. Therefore, it is necessary to investigate the underlying mechanisms of the onset and progression of prostate cancer in order to develop updated therapeutics, as well as preventative strategies. Increasing research has indicated that autophagy has an important role in cancer, which may become an effective drug target in anticancer therapy (3,4).

Cyclooxygenase-2 (COX-2), an inducible iso-enzyme that converts arachidonic acid to prostaglandins, is involved in cancer angiogenesis, apoptosis and invasion (5). Celecoxib is a specific COX-2 inhibitor that competes with arachidonic acid for the active site of cyclooxygenase. Numerous trials have indicated that the regular use of nonsteroidal anti-inflammatory drugs may provide benefits against malignancies (6,7).
In the present study, whether celecoxib was able to induce apoptosis and autophagy in PC3 cells, an androgen-independent cell line, was investigated. Furthermore, whether celecoxib-induced autophagy exerted protective effects in PC3 cells and the underlying mechanism for the induction of autophagy were investigated. The present study also investigated whether the inhibition of autophagy by targeting the activated molecule was able to enhance apoptosis induced by celecoxib.

Materials and methods

Cells and cell culture. Prostate cancer PC3 cells were obtained from Chongqing Key Laboratory of Molecular Oncology and Epigenetics (Chongqing, China). Cells were cultured in RPMI 1640 medium (HyClone; GE Healthcare Life Sciences, Logan, UT, USA) supplemented with 10% fetal bovine serum (FBS; Gibco; Thermo Fisher Scientific, Inc. Waltham, MA, USA), penicillin (100 μg/ml) and streptomycin (100 μg/ml) at 37°C in an atmosphere of 95% air and 5% CO₂.

Reagents and antibodies. Antibodies for phospho-JNK (cat. no. 4668; 1:1,000), JNK1 (cat. no. 3708; 1:1,000) and cleaved-caspase 3 (cat. no. 9664; 1:1,000) were purchased from Cell Signaling Technology, Inc. (Danvers, MA, USA). Anti-poly (ADP-ribose) polymerase (PARP; cat. no. 556494; 1:1,000) antibody and P62 (cat. no. 610497; 1:1,000) were purchased from BD Biosciences (San Jose, CA, USA). Anti-LC3B (cat. no. L7543; 1:1,000) antibody was purchased from Sigma-Aldrich (Merck KGaA, Darmstadt, Germany). Antibodies against β-actin (cat. no. ABM-0001; 1:1,000) and cleaved caspase-3 (cat. no. 9664; 1:1,000) were purchased from Zoonbio Biotechnology Co., Ltd. (Nanjing, China) and both secondary antibodies including goat anti-rabbit IgG-HRP secondary antibody (cat. no. ASS1006; 1:2,000) and goat anti-mouse IgG-HRP secondary antibody (cat. no. ASS1007; 1:2,000) were purchased from Abgent, Inc. (San Diego, CA, USA). The JNK inhibitor SP600125 (cat. no. S1460) and pan-caspase inhibitor z-VAD (cat. no. S7023) were purchased from Selleck Chemicals (Houston, TX, USA). Chloroquine diphosphate (CQ; cat. no. 50-63-5) was purchased from Sigma-Aldrich (Merck Millipore). The autophagy inhibitor 3-methyladenine (3MA; cat. no. sc-205596) was purchased from Santa Cruz Biotechnology, Inc. (Dallas, TX, USA) and dissolved in dimethyl sulfoxide (DMSO; 10 mM) to pretreat the cells prior to the MTT assay, flow cytometry and western blot analysis. Celecoxib (Pfizer Inc., New York, NY, USA) was dissolved in dimethyl sulfoxide (DMSO) and used within 1 month.

Cell viability assay. The effect of celecoxib on cell viability was measured using 3-(4,5-dimethyl thiazol-2-yl)-2,5-di-phenyl tetrazoliumbromide (MTT) assay. Cells were seeded at 5,000-10,000 cells/well in 96-well plates and incubated overnight at 37°C. Following this, different concentrations of celecoxib were added and the plates were incubated for an additional 24 or 48 h at 37°C. Subsequently, 20 μl of MTT solution (5 mg/ml) was added to each well and the cells were incubated for 4 h at 37°C. After removal of the culture medium, 100 μl dimethyl sulfoxide (DMSO) was added per well to dissolve the formazan crystals and the optical density (OD) was measured at 460 nm by a microplate reader. Changes in percentage viability were calculated using the following formula: Cell viability (%) = (OD of the experimental sample / OD of the control group) x 100.

Measurement of apoptosis by flow cytometry. Cell apoptosis was detected using an annexin V-fluorescein isothiocyanate-propidium iodide (PI) kit (Beyotime Institute of Biotechnology, Haimen, China). Cells were collected and suspended in 200 μl medium buffer. Subsequently, ~10 μl annexin V solution was added to the cell suspension solution and the solution was incubated for 15 min in the dark at room temperature. Following this, 300 μl medium buffer and 5 μl PI were added and the cell suspension was immediately analyzed using a flow cytometer. Annexin V-negative/PI-negative represented viable cells, annexin V-positive/PI-negative represented early apoptotic cells, annexin V-positive/PI-positive represented terminal apoptotic cells and annexin V-negative/PI-positive cells represented necrotic cells. Flow cytometry acquired ~10⁶ cells and the data were acquired using a FACSCanto 6-color flow cytometer (BD Biosciences, San Jose, CA, USA) and analyzed using BD FACSDiva™ software version 6 (BD Biosciences).

Western blot analysis. Cells were washed twice with ice-cold phosphate-buffered saline (PBS), lysed in lysis buffer (1% Triton X-100, 50 mM Tris-Cl, pH 7.4, 150 mM NaCl, 10 mM EDTA, 100 mM NaF, 1 mM Na3VO4, 1 mM PMSF and 2 μg/ml apro- tinin) and quantified using bicinchoninic acid (BCA) assay kit (Beyotime Institute of Biotechnology). Equal amounts of denatured protein lysates (40 μg/lane) were separated by 12% SDS-PAGE and transferred to a nitrocellulose membrane (cat. no. CS011-0001; ExCell Biology, Inc., Shanghai, China). Following this, the membranes were blocked with 5% skim milk in Tris-buffered saline-Tween 20 buffer (TBST; 10 mM Tris-HCl pH 7.4, 150 mM NaCl, 0.1% Tween) at room temperature for 2 h and the blots were incubated with the indicated primary antibodies (anti-phospho-JNK, JNK1, LC3B, P62, cleaved caspase 3, PARP, β-actin; 1:1,000) overnight at 4°C. After three 10 min washes with TBST buffer, the membranes were incubated with secondary antibodies (goat anti-rabbit IgG-HRP secondary antibody, goat anti-mouse IgG-HRP secondary antibody; both 1:2,000) for 30 min at room temperature. Following the use of HRP-conjugated IgG secondary antibodies, proteins were detected with an enhanced chemiluminescence reagent (EMD Millipore, Billerica, MA, USA) and visualized using an electrophoresis gel imaging analysis system.

Transmission electron microscopy (TEM). For visualization of the cellular ultrastructure using TEM, celecoxib-treated cells were treated with trypsin, rinsed twice with warm PBS (37°C) and fixed for 1 h in 2.5% glutaraldehyde in 0.1 M cacodylate buffer with 1% sucrose. After washing with PBS, the cells were fixed in 1% osmium tetroxide and embedded in Epon resin. Sections of 0.1-mm thickness were cut and stained with uranyl acetate/lead citrate and visualized under a Hitachi-7,500 TEM (Hitchi, Ltd., Tokyo, Japan).

Statistical analysis. Statistical analysis was conducted using SPSS v.16.0 (SPSS Inc., Chicago, IL, USA). Data was
confirmed in three independent experiments and expressed as the mean ± standard deviation. Differences between groups were evaluated using Student's t-tests. P<0.05 was considered to indicate a statistically significant difference.

**Results**

**Celecoxib decreases cell viability in a dose-dependent and time-dependent manner.** PC3 cells were exposed to celecoxib for 24 and 48 h, respectively, and cell viability was measured using an MTT assay. Results demonstrated that cytotoxicity in PC3 cells was induced by celecoxib in a dose-dependent and time-dependent manner, with all doses of celecoxib resulting in a significant decrease in cell viability compared with the untreated control group at 24 and 48 h (P<0.05; Fig. 1). The 50% inhibitory concentration of celecoxib for 24 h was 100 µmol/l, which was chosen for subsequent experiments.

**Celecoxib induces autophagy in PC3 cells.** To explore whether celecoxib was able to induce autophagy in PC3 cells, the conversion of LC3-I to LC3-II and the degradation of P62 was detected by western blot analysis. Results demonstrated that the conversion of LC3-I to LC3-II increased following treatment with celecoxib; however, P62 degraded gradually as PC3 cells were incubated with celecoxib (100 µmol/l) for 0, 2, 4 and 8 h (Fig. 2A). In order to determine if the observed change in LC3 was due to autophagy, CQ, a lysosome inhibitor for LC3-II turnover, was combined with celecoxib to detect autophagy flux. Results demonstrated that combined exposure to celecoxib and CQ induced a marked increase in LC3-II expression levels compared with celecoxib or CQ alone (Fig. 2B). Furthermore, TEM was used to detect autophagosomes (autophagic vacuoles), which is considered to be the morphological hallmark of autophagy. Results demonstrated that celecoxib induced marked autophagosome formation compared with the control group (Fig. 2C). These results demonstrated that autophagy was induced by celecoxib treatment.

**Celecoxib induces apoptosis in PC3 cells.** In order to determine whether celecoxib-induced cytotoxicity was due to activated apoptosis, western blotting was performed to evaluate expression levels of PARP and caspase 3. Compared with the control group (0 h), the expression levels of PARP and caspase 3 markedly increased in a time-dependent manner (Fig. 3A). To further elucidate whether PC3 cell apoptosis was induced by celecoxib, flow cytometry was applied to compare the following groups: Control group; celecoxib-treated for 8 h; and celecoxib plus the pan-caspase inhibitor zVAD. Flow cytometry indicated that celecoxib was able to induce significant apoptosis (P<0.05) compared with the control group, and zVAD was able to significantly inhibit (P<0.05) celecoxib-induced apoptosis (Fig. 3B and C, respectively).

**Autophagy has a cytoprotective role in celecoxib-induced apoptosis.** To investigate the role of autophagy in celecoxib-induced apoptosis in PC3 cells, cells were pretreated with 3-methyladenine (3MA) to inhibit autophagy before celecoxib exposure (80, 100 and 120 µmol/l). MTT assay results demonstrated that cell viability was significantly reduced (P<0.05) by inhibition of autophagy compared with the celecoxib-only group (Fig. 4A). Furthermore, flow cytometry was used to detect cell apoptosis following pretreatment with 3MA and the results were consistent with the MTT assay results (Fig. 4B). Altogether, these results demonstrated that autophagy may have a protective role in PC3 cells under celecoxib-induced apoptosis.

**Celecoxib-induced apoptosis is mediated by JNK activation.** JNK activation has been demonstrated to be involved in autophagy due to various stresses (8). To investigate whether JNK was activated in celecoxib-induced autophagy, western blot analysis was conducted to detect the phosphorylation of JNK in PC3 cells following exposure to celecoxib (Fig. 5). JNK was activated into pJNK following incubation with celecoxib (100 µmol/l) for 0, 1, 2 and 4 h (Fig. 5A). Furthermore, SP600125, a specific inhibitor of JNK, was able to inhibit the conversion of LC3-I to LC3-II (Fig. 5B) and reduce cell viability by increasing cell apoptosis (Fig. 4). These results demonstrated that JNK was related to celecoxib-induced apoptosis.

**Discussion**

In the present study it was demonstrated that celecoxib was able to induce apoptosis and autophagy in PC3 cells. COX-2, an enzyme involved in cancer angiogenesis, apoptosis and invasiveness, has been associated with poor prognosis in various types of cancer, including rectal and cervical cancer (9,10). Celecoxib is a specific COX-2 inhibitor that is widely used to treat acute pain, rheumatoid arthritis and familial adenomatous polyposis. Previous studies have reported that celecoxib may exert anticancer effects in various human neoplasms, such as lung cancer, breast carcinomas, colorectal cancer and prostate cancer (11-13). A meta-analysis of 11 randomized clinical trials by Chen et al (14) reported that celecoxib was beneficial in the treatment of various types of advanced cancer. Considering the significant role of COX-2 in the regulation of cancer angiogenesis, apoptosis and invasiveness, the molecular mechanisms of COX-2 have been intensively studied in prostate cancer (15,16). A study by Khor et al (17) investigated
the relationship between COX-2 overexpression and outcomes in patients with prostate cancer following radiation treatment and the results demonstrated that COX-2 expression levels were positively associated with biochemical failure and distant metastasis. Furthermore, a study by Patel et al (6) revealed that celecoxib possesses different COX-2-independent anticancer properties, which exert synergic effects with COX-2-dependent effects against prostate cancer growth.

Autophagy, an evolutionarily conserved adaptive cellular process, enables cells to engulf dysfunctional cellular...
proteins and damaged organelles, which eventually fuse with lysosomes for degradation when exposed to metabolic, toxic, hypoxic and infectious stresses (18). Accumulating evidence suggests that autophagy exerts potent anti-cancer mechanisms to suppress tumor initiation (19,20). However, at the advanced stage of cancer, autophagy enables cancer cells to enhance nutrient utilization and improve growth in the context of therapeutic intervention, and so the role of autophagy in cancer is controversial (21,22). Research on beclin 1 autophagy gene deletion in prostate cancer has indicated that autophagy suppresses prostatic tumorigenesis (23,24), whereas other studies have demonstrated that autophagy is a survival mechanism to overcome stresses in prostate cancer (3,25).

Androgen deprivation is considered the backbone of therapy for hormone-sensitive or castration-resistant prostate cancer (26). The underlying mechanism of androgen deprivation and autophagy activation has been demonstrated in vivo as well as in vitro models of prostate cancer (27,28). Specifically, AMP-dependent protein kinase activation leading to the suppression of mammalian target of rapamycin is one of the most investigated mechanisms for autophagy induction in androgen-dependent or androgen-independent models of prostate cancer (29,30).

JNK, a mitogen-activated protein kinase, contributes to apoptotic signal transduction when exposed to various forms of stress (31). JNK target proteins include the transcription factor c-Jun, apoptotic regulatory proteins, such as B-cell lymphoma

Figure 4. (A) Cell viability of celecoxib-treated (80, 100 and 120 µmol/l), celecoxib+3MA and celecoxib+SP groups. (B) Representative dot plots of apoptosis in the control, celecoxib, 3MA, celecoxib+3MA groups, SP and celecoxib+SP groups. Data are presented as the mean ± standard deviation. *P<0.05 vs. 80 µmol/l celecoxib group; †P<0.05 vs. the 100 µmol/l celecoxib group; ‡P<0.05 vs. the 120 µmol/l celecoxib group. 3MA, 3-methyladenine; SP, c-Jun N-terminal kinase inhibitor SP600125.
autophagy, which exerts cytoprotective effects in prostate cancer PC3 cells. JNK is activated in celecoxib-treated cells and, when considering the dual roles of JNK in autophagy and apoptosis, further investigation is required to illustrate the precise underlying mechanisms of JNK. Meanwhile, the blockade of autophagy via the JNK-mediated pathway may provide a promising strategy for prostate cancer therapy.

Acknowledgments

The present study was financially supported by grants from the Natural Science Foundation of China (grant nos. 81370706 and 81372758).

References

1. Center MM, Jemal A, Lortet-Tieulent J, Ward E, Ferlay J, Brawley O and Bray F: International variation in prostate cancer incidence and mortality rates. Eur Urol 61: 1079-1092, 2012.
2. Siegel RL, Miller KD and Jemal A: Cancer statistics, 2015. CA Cancer J Clin 65: 5-29, 2015.
3. Degenhardt K, Mathew R, Beaudoin B, Bray K, Anderson D, Chen G, Mukherjee C, Shi Y, Gelinas C, Fan Y, et al: Autophagy promotes tumor cell survival and restricts necrosis, inflammation and tumorigenesis. Cancer Cell 10: 51-64, 2006.
4. Amaravadi RK and Thompson CB: The roles of therapy-induced autophagy and necrosis in cancer treatment. Clin Cancer Res 13: 7271-7279, 2007.
5. Taketo MM: Cyclooxygenase-2 inhibitors in tumorigenesis (part I). J Natl Cancer Inst 90: 1529-1536, 1998.
6. Patel MI, Subbaramaiah K, Du B, Chang M, Yang P, Newman RA, Cordon-Cardo C, Thaler HT and Dannenberg AJ: Celecoxib inhibits prostate cancer growth: Evidence of a cyclooxygenase-2-independent mechanism. Clin Cancer Res 11: 1999-2007, 2005.
7. Huang S and Sinicrope FA: Celecoxib-induced apoptosis is enhanced by ABT-737 and by inhibition of autophagy in human colorectal cancer cells. Autophagy 6: 256-269, 2010.
8. Li DD, Wang LL, Deng R, Tang J, Shen Y, Guo JF, Wang Y, Xia LP, Feng GK, Liu QQ, et al: The pivotal role of c-Jun NH2-terminal kinase-mediated Beclin 1 expression during anti-cancer agents-induced autophagy in cancer cells. Oncogene 28: 886-898, 2009.
9. Smith FM, Reynolds JV, Kay EW, Crotty P, Murphy JO, Hollywood D, Gaffney EF, Stephens RB and Kennedy MJ: COX-2 overexpression in pretreatment biopsies predicts response of rectal cancers to neoadjuvant radiochemotherapy. Int J Radiat Oncol Biol Phys 64: 466-472, 2006.
10. Ishikawa H, Ohno T, Kato S, Wakatsuki M, Iwakawa M, Ohta T, Imai T, Mitsuhashi N, Nakano T, Tsujii H: Cyclooxygenase-2 impairs treatment effects of radiotherapy for cervical cancer by inhibition of radiation-induced apoptosis. Int J Radiat Oncol Biol Phys 63: 940-951, 2005.
11. Mao JT, Roth MD, Fishbein MC, Aaberle DR, Zhang ZF, Rao JY, Tashkin DP, Goodgluck L, Holmes EC, Cameron RB, et al: Lung cancer chemoprevention with celecoxib in former smokers. Cancer Prev Res (Phila) 4: 984-993, 2011.
12. Perroud HA, Rico MJ, Alasino CM, Queralt F, Mainetti LE, Pezzotto SM, Rozados VR and Scharovsky OG: Safety and therapeutic effect of metronomic chemotherapy with cyclophosphamide and celecoxib in advanced breast cancer patients. Future Oncol 9: 451-462, 2013.
13. Basler JW and Piazza GA: Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 selective inhibitors for prostate cancer chemoprevention. J Urol 171: S59-S63, 2004.
14. Shen J, Shen P, Zhang XC, Zhao MD, Zhang XG and Yang L: Efficacy and safety profile of celecoxib for treating advanced cancers: A meta-analysis of 11 randomized clinical trials. Clin Ther 36: 1253-1263, 2014.
15. Hussian T, Gupta S and Mukhtar H: Cyclooxygenase-2 and prostate carcinogenesis. Cancer Lett 191: 125-135, 2003.
16. Apalrico Gallego G, Díaz Prado S, Jiménez Fonseca P, García Campelo R, Cassinello Espinosa J and Antón Aparicio LM: Cyclooxygenase-2 (COX-2): A molecular target in prostate cancer. Clin Transl Oncol 9: 694-702, 2007.
Khor LY, Bae K, Pollack A, Hammond ME, Grignon DJ, Venkatesan VM, Rosenthal SA, Ritter MA, Sandler HM, Hanks GE, et al: COX-2 expression predicts prostate-cancer outcome: Analysis of data from the RTOG 92-02 trial. Lancet Oncol 8: 912-920, 2007.

Ziparo E, Petruungaro S, Marini ES, Starace D, Conti S, Facchiano A, Filippini A and Giampietri C: Autophagy in prostate cancer and androgen suppression therapy. Int J Mol Sci 14: 12090-12106, 2013.

Gozuacik D and Kimchi A: Autophagy as a cell death and tumor suppressor mechanism. Oncogene 23: 2891-2906, 2004.

Jin S: P53, Autophagy and tumor suppression. Autophagy 1: 171-173, 2005.

Ozpolat B and Benbrook DM: Targeting autophagy in cancer management-strategies and developments. Cancer Manag Res 7: 291-299, 2015.

Chen L, Jiang K, Jiang H and Wei P: MiR-155 mediates drug resistance in osteosarcoma cells via inducing autophagy. Exp Ther Med 8: 527-532, 2014.

Aita VM, Liang XH, Murty VV, Pincus DL, Yu W, Cayanis E, Kalachikov S, Gilliam TC and Levine B: Cloning and genomic organization of beclin 1, a candidate tumor suppressor gene on chromosome 17q21. Genomics 59: 59-65, 1999.

Qu X, Yu J, Bhagat G, Hibshoosh H, Troxel A, Rosen J, Eskelinen EL, Mizushima N, Ohsumi Y, et al: Promotion of tumorigenesis by heterozygous disruption of the beclin 1 autophagy gene. J Clin Invest 112: 1809-1820, 2003.

Kung HJ: Targeting tyrosine kinases and autophagy in prostate cancer. Horm Cancer 2: 38-46, 2011.

Merseburger AS, Hammerer P, Rozet F, Roumeguère T, Caffo O, da Silva PC and Alcaraz A: Androgen deprivation therapy in castrate-resistant prostate cancer: How important is GnRH agonist backbone therapy? World J Urol 33: 1079-1085, 2015.

Nguyen HG, Yang JC, Kung HJ, Shi XB, Tilki D, Lara PN Jr, Devere White KW, Gao AC and Evans CP: Targeting autophagy overcomes enzalutamide resistance in castration-resistant prostate cancer cells and improves therapeutic response in a xenograft model. Oncogene 33: 4521-4530, 2014.